Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Obinutuzumab Versus Rituximab in Combination With Chemotherapy for Adult Patients With Newly Diagnosed CD20-positive Acute Lymphoblastic Leukemia

NCT04920968 is registered in ClinicalTrials.gov with Maria Sklodowska-Curie National Research Institute of Oncology as lead sponsor.

NCT NCT04920968
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04920968 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Obinutuzumab Versus Rituximab in Combination With Chemotherapy for Adult Patients With Newly Diagnosed CD20-positive Acute Lymphoblastic Leukemia
Lead sponsor
Maria Sklodowska-Curie National Research Institute of Oncology
Phase
Phase 2
Overall status
Recruiting
Start date
October 5, 2021
Completion date
December 31, 2025
Enrollment
124 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

cd20-positive acute lymphoblastic leukemia